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Abstract
Arteriovenous fistula (AVF) is regarded as the best vascular access for chronic haemodialysis (HD). Still, AVF inherently
causes significant haemodynamic changes. Although the necessity for vascular access despite its putative cardiovascular
complications favours AVF creation in patients under chronic HD, one may question whether sustaining a functional AVF
after successful kidney transplantation extends the haemodynamic threat. Small prospective series suggest that AVF
ligation causes rapid and sustained reduction in left ventricular hypertrophy. Still, the benefits of such a cardiac
remodelling in long-terms of cardiovascular morbi-mortality still need to be proven. Furthermore, the elevation of diastolic
blood pressure and arterial stiffness caused by AVF ligation may blunt the expected cardio-protection. Finally, the closure of
a functioning AVF may accelerate the decline of kidney graft function. As a whole, the current management of a
functioning AVF in kidney transplant recipients remains controversial and does not rely on strong evidence-based data.
The individual risk of graft dysfunction and a return to chronic HD also needs to be balanced. Careful pre-operative
functional assessments, including cardio-pulmonary testing and estimated glomerular filtration rate slope estimation, may
help better selection of who might benefit the most from AVF closure. Large-scale prospective, ideally multi-centric, trials
are essentially needed.
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Introduction
Arteriovenous fistula (AVF) is regarded as the best vascular ac-
cess for chronic haemodialysis (HD) in patients with end-stage
renal disease (ESRD) [1, 2]. AVF provides better patient access
and survival in comparison to arteriovenous grafts and central
venous catheters, because with fewer access-related infections
and endovascular interventions [3–5]. Efficient HD requires a
flow rate of 400–600 mL/min. Since the brachial flow only
reaches 60–120 mL/min in physiological conditions, a
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permanent vascular access needs to be surgically created on the
basis of vessel mapping studies. A distal-to-proximal approach
starting from the non-dominant arm is preferred to preserve
patients’ quality of life, as suggested in K/DOQI guidelines. AVF
referral within 12 months of the estimated time to dialysis
performed best among time frame strategies, although the tim-
ing of referral is classically guided by the patient’s age and by
his/her individual likelihood and rate of progression to ESRD
[6, 7]. The AVF flows in the forearm usually reach 500–900 mL/
min, whereas those in the upper arm are 900–1500 mL/min
[2, 8]. Inherently, AVF causes significant haemodynamic
changes in patients under chronic HD, which may lead to ser-
ious complications, including arterial steal, pulmonary hyper-
tension (PH) and high-output cardiac failure [9]. As a reminder,
high-flow accesses have been defined as flows between 1 and
1.5 L/min and/or >20% of the cardiac output (CO) [10].
Although the necessity for vascular access despite its puta-
tive increased risk of cardiovascular complications favours AVF
creation in patients under chronic HD, one may question
whether sustaining a functional AVF after kidney transplant-
ation (KTx) extends such a haemodynamic threat [11–13]. A con-
trario, the AVF-associated hyperdynamic circulation has been
suggested to reduce blood pressure (BP) and arterial stiffness, as
well as to preserve kidney function in patients with advanced
chronic kidney disease (CKD) [14–16]. Nowadays, there is no
consensus concerning the strategy between surgical ligation
versus watchful preservation of a functioning AVF in kidney
transplant recipients (KTRs) with a well-functioning graft [17].
The present review aims at summarizing the scientific evidence
concerning AVF impacts on renal and cardiovascular functions
at the successive stages of kidney disease, i.e. pre-terminal
CKD, chronic HD and post-KTx.
Global haemodynamic impacts of AVF
In the non-transplant population with CKD, the creation of an
AVF for the purpose of HD initiation has been reported to slow
down CKD progression [15, 16]. Golper et al. [15] retrospectively
observed in a series of 123 CKD patients that AVF surgery was
associated with a significant deceleration of estimated glom-
erular filtration rate (eGFR) slope decline from 5.9 to 0.5 mL/
min/year. These intriguing observations were confirmed in a
nationwide cohort of 3026 CKD US veterans: a significant reduc-
tion of eGFR loss was observed following AVF creation (from
5.6 to 4.1 mL/min/1.73 m2/year) [16]. These clinical findings
may be partly explained by the pathophysiological cascades of
remote ischaemic preconditioning [18]. AVF causes brief, but re-
peated, periods of local ischaemia, thereby inducing systemic
protection against tissue hypoperfusion. AVF also adds a low-
resistance, high-compliance venous compartment to the arter-
ial system, which may attenuate both arterial stiffness and
pressure load [14]. In animals, experimental AVF acutely de-
creases BP and increases pulse pressure, whereas fistula closure
restores BP to normal levels by modulating sodium excretion
[19–21]. Similar observations were made in humans [22]. Within
14 days following AVF creation, the secretion of the atrial natri-
uretic peptide is induced by volume loading, whereas the re-
lease of brain natriuretic peptide is stimulated by progressive
left ventricle (LV) diastolic dysfunction [23]. In an open-label,
multicentre, prospective, randomized, controlled trial, Lobo
et al. [22, 24] demonstrated that implanting a central iliac ar-
teriovenous coupler in patients with uncontrolled hypertension
produced a marked reduction in average 24-h ambulatory BP at
6 months and significantly reduced hypertensive complications.
This clinical trial included 83 patients randomly allocated in a
1:1 ratio to undergo implantation of an arteriovenous anasto-
mosis plus current pharmaceutical treatment or to maintain
current treatment alone (controls). Mean systolic 24-h ambula-
tory BP reduced by 13.5 mmHg (P<0.0001 versus baseline) in ar-
teriovenous coupler recipients and by 0.5 mmHg (P¼0.86 versus
baseline) in controls. Physiologically, the addition of a low-
resistance, high-compliance venous segment in parallel to the
systemic arterial circulation reduces overall systemic vascular
resistance (SVR), similar to Ohm’s law of electrical resistance
[25]. Cardiac afterload is further reduced by the reduction of ef-
fective arterial volume and arterial stress, and the slowing of re-
flected pressure waves [25]. Reduction of distending BP in the
aorta may also improve arterial compliance, thereby generating
a feed-forward loop based on reduced SVR, improved compli-
ance and reduced BP and the long-term beneficial cardiac and
aortic remodelling. Finally, AVF-mediated venous return neces-
sarily favours pulmonary flow, which may in turn recruit larger
lung areas and increase arterial oxygen content [26]. One may
thus advocate that AVF favourably influence CKD progression
by improving oxygen delivery to the kidney, thereby attenuating
the vasoconstrictive renal chemo-reflex [18, 27] (Figure 1).
These encouraging data may be challenged by the adverse
impact of AVF on the balance between poorer subendocardial
oxygen supply and increased oxygen demand consequent to a
greater CO [28, 29] (Figure 1).
Haemodynamic impacts of high-flow AVF in
patients under chronic HD
AVF has been associated with various haemodynamic compli-
cations in patients under chronic HD, including arterial steal,
PH and high-output cardiac failure. The first clinical manifest-
ation of arterial ‘steal’ was reported in 1969 [30, 31]. Patients
with steal progressively develop mild paraesthesia, persistent
Fig. 1. Schematic summary of haemodynamic changes caused by the creation
vs. ligation of an arteriovenous fistula. ANP, atrial natriuretic peptide; BP, blood
pressure; LV, left ventricle; vasoC, vasoconstrictive.
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pain, motor dysfunction and ulcerations, which correspond to
ischaemic neuropathy [32]. Risk factors for the development of
arterial steal include diabetes mellitus, tobacco use, female gen-
der, advanced age, prior ipsilateral arteriovenous access place-
ment and peripheral arterial disease [33]. HD-related steal
seems to occur more frequently with brachial AVF than with ra-
dial or ulnar fistulas. In a systematic review of the Medline lit-
erature (from 2000 to 2014, including 43 English-written reports
of prospective trials), Al-Jaishi et al. [34] concluded that the me-
dian complication rate of steal events per 1000 patient days was
0.05. The authors acknowledged that the risk of bias was high
and event rates were highly variable, partly due to poor quality
studies, significant heterogeneity of study populations and in-
consistent definitions of ‘steal syndrome’.
PH secondary to high-flow AVF has been reported [35]. PH is
defined as a mean pulmonary artery pressure 25 mmHg at rest
and concerns 40–48% of the population receiving long-term HD
via surgical AVF [35–37]. Both ESRD and AVF are thought to partici-
pate in PH development [38]. Hormonal and metabolic perturb-
ations caused by ESRD induce pulmonary arterial vasoconstriction
and elevated pulmonary vascular resistance. Pulmonary arterial
pressure may be further increased by the AVF-associated high CO,
anaemia and fluid overload. Mortality among PH patients is three
times higher compared with those without PH [37].
High-output cardiac failure is characterized by signs and
symptoms (i.e. dyspnoea, orthopnoea, paroxysmal dyspnoea
and pulmonary and/or peripheral oedema) of systemic conges-
tion in combination with a CO >8.0 L/min and/or a cardiac index
>4.0 L/min/m2 [39, 40]. LV ejection fraction is usually preserved.
In such a typical case of chronic volume overload, normal sys-
tolic function and low mass-to-volume ratio, the clinical out-
come appears more dependent on LV dilatation than LV
hypertrophy [41]. Still, LV hypertrophy is highly prevalent
among patients with ESRD, and is an independent predictor of
morbi-mortality in patients under chronic HD [42, 43]. LV hyper-
trophy results from combined effects of chronic haemodynamic
overload, including increased flow and pressure, and non-hae-
modynamic biochemical and neurohumoral factors, including
anaemia, chronically elevated fibroblast growth factor 23, hypo-
albuminaemia and uraemic toxins [43, 44]. Age and diabetes
also participate in LV hypertrophy. The HD-associated LV
hypertrophy is mostly eccentric, with increased LV mass and
relatively normal wall thickness. Early observations estimated
that when >20% of the CO is shunted through the AVF, it predis-
poses to cardiac failure [31]. Reddy et al. [9] retrospectively char-
acterized the long-term changes in cardiac structure and
function in 137 patients undergoing AVF creation for chronic
HD. Of important note, the monocentric observational design of
this study, with no control group, does not allow separation of
the beneficial effects of chronic HD (including volume removal)
from the deleterious haemodynamic effects of the AVF. Still,
after a median follow-up of 2.6 years post-AVF and HD initi-
ation, Reddy et al. observed reductions in BP, body weight and
estimated plasma volume coupled with modest reverse LV
remodelling, which may reflect decreased LV pressure load
from efficient renal replacement therapy. In contrast, AVF cre-
ation was associated with significant right ventricle (RV) dilata-
tion and deterioration in RV function. Similar observations were
reported in a longitudinal series including 24 ESRD patients [45].
Sequential cardiac magnetic resonance imaging (MRI) showed
significant increases in LV and RV end-systolic volumes, left
and right atrial area and LV mass following AVF creation. No
significant change in aortic distensibility was identified. Note
that such AVF-induced RV dilation has been independently
associated with increased risk of death [9]. Buchanan et al. [46]
recently performed a comprehensive study of the cardiovascu-
lar impact of HD sessions using intradialytic cardiac MRI in 12
stable patients. Cardiac MRI measurements included cardiac
index, stroke volume index, global and regional contractile
function (myocardial strain), coronary artery flow and myocar-
dial perfusion. All measures of systolic contractile function
dropped during HD, with partial recovery after dialysis. All pa-
tients experienced some degree of segmental LV dysfunction,
with severity proportional to ultrafiltration rate and BP reduc-
tion. Myocardial perfusion decreased significantly during HD
session [46]. In a single centre between 2003 and 2006, Movilli
et al. [47] enrolled 25 consecutive HD patients who underwent
AVF ligation and conversion to a tunnelled central venous
catheter, and compared them with 36 controls with a well-
functioning AVF. Outcomes were changes in echocardiographic
parameters obtained before and 6 months after AVF closure for
patients in the AVF-closure group, and at baseline and 6 months
later for controls. Closure of the AVF caused a significant de-
crease in LV internal diastolic diameter, interventricular septum
thickness and diastolic posterior wall thickness. This was asso-
ciated with a significant decrease in LV mass and a more
favourable shift of cardiac geometry towards normality.
To date, there is no consensus as to the threshold flow val-
ues in the management of steal syndrome, PH and cardiac fail-
ure in patients under chronic HD [48, 49]. The causal link
between access flow and increased morbi-mortality probably
exists, but still needs to be directly proven [8, 50].
Haemodynamic impacts of AVF in patients
following KTx
The impact of patent AVF after successful KTx on cardiac
morphology and function remains largely controversial. On one
hand, the persistence of large high-flow AVF for prolonged peri-
ods of time has been reported to have little influence on heart
parameters in 61 stable KTRs with adequate renal function (i.e.
serum creatinine level <2 mg/dL) [12]. On the other hand, the
maintenance of long-lasting AVF has been independently asso-
ciated with LV hypertrophy in a monocentric cohort of 162 KTRs
[11]. LV hypertrophy, with uncontrolled hypertension and per-
sistent anaemia, contributes to the increased cardiac mortality
observed among KTRs [51, 52]. Furthermore, high-output car-
diac failure secondary to high-flow AVF might be a frequent
condition in the KTR population. In a retrospective study
including 113 KTRs with a functioning AVF, 25.7% required AVF
ligation for clinical suspicion of cardiac failure. The mean shunt
flow in the intervention group was 2197.2 mL/min, whereas the
mean shunt flow in the non-intervention group was only
850.9 mL/min [53].
The impact of surgical ligation of the AVF on cardiovascular
parameters has been studied in both observational cohorts and
prospective studies including a limited number of transplant
patients [12, 19, 47, 54–58] (Figure 1). In a retrospective mono-
centric cohort, Soleimani et al. [57] showed that spontaneous
AVF thrombosis in 17 KTRs does not cause significant LV struc-
tural modifications compared with 23 control KTRs with a func-
tioning AVF. Similarly, Glowinski et al. [58] reported in a
prospective series of nine KTRs with normal-flow AVF that AVF
ligation (n¼ 5) or thrombosis (n¼ 4) does not significantly im-
pact cardiac function after a 3-month follow-up, in comparison
with nine age- and gender-matched controls with a functioning
AVF. By strong contrast, Unger et al. [55] demonstrated that AVF
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surgical ligation reduced LV end-diastolic diameter and mass
indexes within 10 weeks post-surgery, in a prospective series of
17 stable KTRs. Note that the interventricular septum thickness
remained unchanged, and a slight but significant increase in
posterior wall thickness was observed. Diastolic and mean ar-
terial BP slightly, but significantly, increased following AVF liga-
tion [55]. These observations were confirmed after a long-term
follow-up of 21 months [56]. Interestingly enough, post-opera-
tive reductions in LV hypertrophy could be predicted by the dy-
namic increase in total peripheral resistance (TPR) and BP
observed during an acute occlusion of the AVF by pneumatic
compression. Hence, an increase in TPR of more than a third of
baseline value predicted a 5% reduction in LV end-diastolic
diameter index with positive predictive value of 80%. Similarly,
an increase in BP during pneumatic compression of >10% of
baseline predicted a 5% reduction in LV end-diastolic diameter
index with a positive predictive value of 88% [55]. van
Duijnhoven et al. [54] found a correlation between pre-operative
LV mass and LV end-diastolic diameter and the reduction in LV
mass as determined 4–5 months following AVF ligation.
Such a beneficial flow-dependent impact of AVF ligation on
LV mass reduction may be partly blunted by the concurrent in-
crease of arterial BP and TPR, as well as by the persisting abnor-
malities in LV geometry [29]. In a well-designed prospective
study including 16 KTRs, the 24-h ambulatory blood pressure
monitoring (ABPM) showed a significant increase of diastolic BP,
with no systolic changes, at 1 month after surgical AVF closure
[19]. BP remained unchanged within a similar time frame in 14
KTRs with a functioning fistula. It is important to remember
that 24-h ABPM better assesses BP load, better correlates with
target organ lesions and has superior prognostic significance
compared with single BP measurement [59]. Since hypertension
negatively influences long-term outcomes after KTx, the clinical
benefits of LV mass reduction after AVF ligation may be unbal-
anced by BP increase [29]. Moreover, in hypertensive CKD pa-
tients, the concentric pattern of LV hypertrophy, which
corresponds to the predominant geometry after AVF ligation,
represents an independent prognostic factor of cardiovascular
events [60, 61]. Finally, Ferro et al. [62] reported in 250 stable
KTRs that the presence of a functioning AVF independently cor-
related with an increased aortic augmentation index (calculated
by non-invasive pulse wave exploration) on the basis of a multi-
variate analysis (Table 1).
Concerning the evolution of renal graft function, Vajdic et al.
retrospectively showed in a historical cohort including 311 KTRs
that patients with a functioning AVF at 1 year post-KTx
(69621 mL/min/1.73 m2, n¼ 239) had significantly lower
Modification of Diet in Renal Disease (MDRD) eGFR values than
those with spontaneously closed AVF (746 19 mL/min/1.73 m2,
n¼ 72). Adjusted analyses suggested that AVF persistence was
Table 1. Summary of the main observations post ligation of functioning AVF in KTRs
Study Year KTRs (n) Techniques Main findings
Retrospective
De Lima et al. [12] 1999 61 Echocardiography AVF patency
• Little impact on cardiac morphology and function
Soleimani et al. [57] 2012 40 Echocardiography AVF thrombosis
• No impact on LV morphology
Schier et al. [53] 2013 113 AVF ligation in 25.7% of KTRs for suspected cardiac failure
Kolonko et al. [11] 2014 162 Echocardiography AVF patency
• LV hypertrophy
Weekers et al. [13] 2017 99 eGFR slope AVF ligation
• Accelerated eGFR decline
Prospective
van Duijnhoven et al. [54] 2001 20 Echocardiography (12–16 weeks) AVF ligation
• Improvement in LV hypertrophy
• Reduction in LV end-diastolic diameter
Unger et al. [55] 2002 17 Echocardiography (10 weeks) AVF ligation
• Reduction in LV end-diastolic diameter
• Reduction in LV mass index
• Increase of diastolic arterial BP
Unger et al. [56] 2004 17 Echocardiography (21 weeks) AVF ligation
• Reduction in LV end-diastolic diameter
• Reduction in LV mass index
• Increase of diastolic arterial BP
Unger et al. [19] 2008 16 24 h ABPM (4 weeks) AVF ligation
• Increase of diastolic arterial BP
Movilli et al. [47] 2010 61 Echocardiography (24 weeks) AVF ligation
• LV normal or concentric remodelling
Glowinski et al. [58] 2012 18 Echocardiography (12 weeks) AVF ligation
• No impact on cardiac function
Transversal
Ferro et al. [62] 2002 250 Pulse wave AVF patency
• Increased arterial stiffness
Vajdic et al. [63] 2010 311 eGFR AVF ligation
• Better renal function at 1-year AVF patency
• Increased risk of graft loss
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associated with an increased risk allograft loss [63]. Note that this
retrospective cohort only considered patients with AVF at the
time of KTx, and excluded 91 KTRs because of early graft loss,
non-functioning kidneys, technical failures or deaths during the
first year post-KTx. Kidney graft function was transversally com-
pared at 1 year post-KTx, with no consideration for eGFR slopes.
Consequently, the main limitation of this observational retro-
spective cohort concerns the complete identification of inequities
between groups. Ultimately, the physicians in charge may bias-
edly decide not to close the functioning AVF in patients at higher
risk for CKD progression and ESRD. In a retrospective monocen-
tric study including 285 KTRs, we investigated whether the clos-
ure of a functioning AVF significantly influenced eGFR slope
(calculated using linear mixed models based on MDRD equation)
post-KTx. AVF closure occurred at 6536 441 days post-KTx, with
a thrombosis/ligation ratio of 19/95. In order to limit the unavoid-
able influence of transplantation vintage on eGFR slope, we first
matched the follow-up periods before versus after AVF closure
for every single patient. Hence, we found that the closure of a
functioning AVF significantly accelerates eGFR decline over the
consecutive 12-month period [13].
Conclusions and perspectives
The present review highlights that the current management of
functioning AVF following KTx remains largely controversial
(Figure 1). Surgical ligation is usually performed in patients with
specific indications, like high-flow fistula with arterial steal, LV
dilation, high-risk cardiovascular status or cosmetic reasons.
The possible threat of graft dysfunction and a return to chronic
HD also need to be discussed with the patient. The creation of a
novel efficient AVF in case of ESRD may be extremely difficult in
KTRs and not always feasible when peripheral veins are
exhausted.
Small prospective series suggest that AVF ligation causes
rapid and sustained reduction in LV hypertrophy [55, 56]. Still,
the benefits of such a cardiac remodelling in long terms
of cardiovascular morbi-mortality still need to be proven.
Furthermore, as emphasized by Unger and Wissing [29],
the subsequent elevation of diastolic BP and evolution toward
LV concentric geometry (with increased wall thickness) may
blunt the cardio-protection expected from AVF closure [19].
Furthermore, the closure of a functioning AVF may accelerate
the decline of kidney graft function [13]. Therefore, careful
pre-operative functional assessments, including the dynamic
response of TPR and BP to a transient pneumatic occlusion of
the AVF [55] and the calculation of MDRD-eGFR slope [64], may
help better selection of KTRs who might benefit the most from
AVF closure. Additionally, BP levels should be systematically
monitored following AVF surgery, a fortiori when pre-operative
diastolic BP is >90 mmHg. These assumptions do not rely on
strong evidence-based data, and definitely need to be tested in
large-scale prospective, ideally multi-centric, populations.
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